Syrbactin proteasome inhibitor TIR-199 overcomes bortezomib chemoresistance and inhibits multiple myeloma tumor growth in vivo. [electronic resource]
Producer: 20200714Description: 106271 p. digitalISSN:- 1873-5835
- Amides -- administration & dosage
- Animals
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Azoles -- administration & dosage
- Bortezomib -- administration & dosage
- Cell Line, Tumor
- Cell Proliferation -- drug effects
- Drug Resistance, Neoplasm -- drug effects
- Drug Synergism
- Humans
- Male
- Mice
- Mice, Inbred C57BL
- Mice, Inbred NOD
- Mice, SCID
- Mice, Transgenic
- Multiple Myeloma -- drug therapy
- Peptides, Cyclic -- chemistry
- Proteasome Inhibitors -- administration & dosage
- Tumor Burden -- drug effects
- Xenograft Model Antitumor Assays
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.